For adults with a BMI ≥30 kg/m² or BMI ≥27 kg/m² with a weight-related comorbidity, along with diet and exercise.[1]

The journey to **lasting change** starts today

The only once-weekly GLP-1 RA for chronic weight management with significant, sustained weight loss[1]*



Learn more about Wegovy® at:
WegovyPro.com

Study design: STEP 1: A 68-week placebo-controlled study of 1,961 adults with obesity (BMI ≥30 kg/m²) or with overweight (BMI 27 kg/m²-29.9 kg/m²) and at least 1 weight-related comorbid condition, such as treated or untreated dyslipidemia or hypertension; patients with type 2 diabetes mellitus were excluded. Patients were randomized 2:1 to receive Wegovy® or placebo; patients in both arms received instruction for a reduced-calorie diet and increased physical activity. During the trial, 17% of patients in the Wegovy® arm discontinued treatment compared with 22% in the placebo arm.[1,2]

*14.9% mean weight loss with Wegovy® 2.4 mg vs 2.4% mean weight loss with placebo at 68 weeks. Mean baseline body weight: Wegovy®=232.4 lb; placebo=231.9 lb. Mean baseline BMI: 37.9 kg/m². BMI, body mass index; GLP-1 RA, glucagon-like peptide-1 receptor agonist.

Indications and Usage

Wegovy® (semaglutide) injection 2.4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in:

- adults with an initial body mass index (BMI) of ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
- pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater standardized for age and sex (obesity)

Limitations of Use

- Wegovy® contains semaglutide and should not be coadministered with other semaglutide-containing products or with any GLP-1 receptor agonist
- The safety and effectiveness of Wegovy® in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established
- Wegovy® has not been studied in patients with a history of pancreatitis

Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

- **In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Wegovy® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined**
- **Wegovy® is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Wegovy® and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Wegovy®**

novo nordisk®

Please see additional Important Safety Information throughout.
Please click here for Prescribing Information, including Boxed Warning.

ONCE-WEEKLY wegovy® semaglutide injection 2.4 mg

Dosing designed with your adult patients in mind[1]

Gradual Wegovy® dose escalation allows patients time to adjust to treatment

Dose-escalation schedule[1]

Start your adult patients with once-weekly Wegovy® at 0.25 mg and escalate the dose every 4 weeks.

The maintenance dose of Wegovy® in adults is either 2.4 mg (recommended) or 1.7 mg once-weekly. Consider treatment response and tolerability when selecting the maintenance dose.

- Follow the dose-escalation schedule to minimize gastrointestinal adverse reactions[1]

Injected subcutaneously once weekly.
The 0.25 mg, 0.5 mg, and 1 mg once-weekly doses are initiation and escalation doses and are not approved as maintenance doses for chronic weight management.[1]

Important Safety Information (cont'd)

Contraindications

- Wegovy® is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy®. Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with Wegovy®

Warnings and Precautions

- **Risk of Thyroid C-Cell Tumors:** Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging

What to do if patients...

Need additional time to adjust to Wegovy®[1]:

If patients do not tolerate a dose during dose escalation:
Consider delaying dose escalation for 4 weeks.

Miss dose(s) of Wegovy®[1]:

Patients miss a dose and the next dose is:

>2 days away (48 hours):
Instruct them to administer Wegovy® as soon as possible.

<2 days away (48 hours):
Inform them to NOT administer a dose of Wegovy®.
Resume dosing on the regularly scheduled day of the week.

Patients miss more than 2 consecutive doses:

Inform them to resume dosing as scheduled. Or if needed, inform them to reinitiate Wegovy® and follow the dose-escalation schedule, which may reduce the occurrence of GI symptoms associated with reinitiation of treatment.

GI, gastrointestinal.

Important Safety Information (cont'd)

Warnings and Precautions (cont'd)

- **Acute Pancreatitis:** Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Acute pancreatitis was observed in patients treated with Wegovy® in clinical trials. Observe patients carefully for signs and symptoms of acute pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by vomiting). If acute pancreatitis is suspected, discontinue Wegovy® promptly, and if acute pancreatitis is confirmed, do not restart

Please see additional Important Safety Information throughout.
Please click here for Prescribing Information, including Boxed Warning.

ONCE-WEEKLY wegovy® semaglutide injection 2.4 mg

Get to know the Wegovy® pen

The only GLP-1 RA for chronic weight management with once-weekly dosing

One and done
Single-use pen that patients dispose of after 1 use[1]

No dose dialing
Patients administer a preset dose for accurate dose delivery[1]

Autoinjector with an integrated 29G needle
Patients will not need to see or handle a needle[1]

~10 SECONDS

How to use the Wegovy® pen[1]

Please refer to Instructions for Use for complete instructions.

push		Push pen firmly against the skin.
click 1		Injection has started.
click 2		Keep applying pressure until the yellow bar has stopped moving.
✓		**Yellow bar has stopped moving.** **The injection is complete.** Lift the pen slowly from skin.

If the first click isn't heard and the yellow bar in the window does not start moving, press the pen more firmly against the skin.

If medicine appears on the skin or leaks during injection, during the next injection keep applying pressure until the yellow bar has stopped moving.

Important Safety Information (cont'd)

Warnings and Precautions (cont'd)

- **Acute Gallbladder Disease:** Treatment with Wegovy® was associated with an increased occurrence of cholelithiasis and cholecystitis. The incidence of cholelithiasis and cholecystitis was higher in Wegovy® pediatric patients aged 12 years and older than in Wegovy® adults. In clinical trials in adult patients, cholelithiasis was reported by 1.6% of Wegovy® patients and 0.7% of placebo patients. Cholecystitis was reported by 0.6% of Wegovy® patients and 0.2% of placebo patients. In a clinical trial in pediatric patients aged 12 years and older, cholelithiasis was reported by 3.8% of Wegovy® patients and 0% placebo patients. Cholecystitis was reported by 0.8% of Wegovy® pediatric patients and 0% placebo patients. Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in Wegovy® patients than in placebo patients, even after accounting for the degree of weight loss. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated

How to administer Wegovy®

Once weekly, on the same day each week, at any time of day[1]

With or without meals[1]

The injection time of day and site can be changed without dose adjustment.[1]

Only administer if the solution is clear, colorless, and contains no particles.[1]

Choosing an injection site



Upper arms

Stomach
(keep 2 inches away from belly button)

Upper legs
(front of thighs)

If there are problems injecting, change to a more firm injection site, such as upper leg, upper arm, or consider standing up while injecting into the lower stomach. The injection site can be in the same body area each week, but refrain from injecting in the same spot each time.

How to store Wegovy®[1]

Keep the Wegovy® single-dose pens refrigerated between 36 °F to 46 °F (2 °C to 8 °C).

Before removing the cap, the pen can be kept from 46 °F to 86 °F (8 °C to 30° C) up to 28 days.

Do not freeze.

Protect Wegovy® from light.

Wegovy® must be kept in the original carton until time of administration.

Discard the Wegovy® pen after use.

Important Safety Information (cont'd)

Warnings and Precautions (cont'd)

- **Hypoglycemia:** Wegovy® lowers blood glucose and can cause hypoglycemia. In a trial of adult patients with type 2 diabetes, hypoglycemia was reported in 6.2% of Wegovy® patients versus 2.5% of placebo patients. Patients with type 2 diabetes taking Wegovy® with an insulin secretagogue (e.g. sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms. Monitor blood glucose in patients with type 2 diabetes

Please see additional Important Safety Information throughout.
Please click here for Prescribing Information, including Boxed Warning.

ONCE·WEEKLY wegovy® semaglutide injection 2.4 mg

Understanding the Wegovy® safety profile can help set expectations

The most common adverse events in Wegovy® clinical trials were gastrointestinal[1]

In clinical trials[1]

- **6.8%** of patients treated with Wegovy® and **3.2%** of patients treated with placebo permanently discontinued treatment as a result of adverse reactions
- Permanent discontinuation of treatment as a result of a gastrointestinal adverse reaction occurred in **4.3%** of patients treated with Wegovy® vs **0.7%** of patients treated with placebo
- The most common adverse reactions leading to discontinuation were: nausea (**1.8%** vs **0.2%**), vomiting (**1.2%** vs **0%**), and diarrhea (**0.7%** vs **0.1%**) for Wegovy® and placebo, respectively
- Adverse reactions observed with Wegovy® 1.7 mg were similar to those reported with Wegovy® 2.4 mg

In STEP 4: ~9 out of 10 patients achieved the 2.4 mg dose at week 20[1]

At week 20, 89% of patients achieved a full dose and were randomized, while 11% did not continue in the trial. The most common reason was adverse reactions (n=48, 5.3%).

Study design

STEP 4: A 68-week trial of 902 adults with obesity (BMI ≥30 kg/m^2) or with overweight (BMI 27 kg/m^2-29.9 kg/m^2) and at least 1 weight-related comorbid condition, such as treated or untreated dyslipidemia or hypertension; patients with type 2 diabetes mellitus were excluded. All patients received Wegovy® during the run-in period of 20 weeks, which included 16 weeks of dose escalation. 803 patients achieved Wegovy® 2.4 mg dose and were then randomized in a 2:1 ratio to either continue on Wegovy® or receive placebo. All patients received instruction for a reduced-calorie diet (~500 kcal/day deficit) and increased physical activity counseling (recommended to a minimum of 150 min/week) throughout the trial.

Important Safety Information (cont'd)

Warnings and Precautions (cont'd)

- **Acute Kidney Injury:** There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which in some cases required hemodialysis, in patients treated with semaglutide. Patients with renal impairment may be at a greater risk of acute kidney injury, but some events have been reported in patients without known underlying renal disease. A majority of the events occurred in patients who experienced nausea, vomiting, or diarrhea, leading to volume depletion.

Help patients understand and manage symptoms during Wegovy® treatment

Nausea was generally mild or moderate and transient[2]

STEP 1: Reported nausea[3]
Median duration 8 days



In clinical trials, nausea was reported in both treatment arms and was most prevalent during the dose-escalation period.[1]

Nausea was not prospectively measured at each patient visit in the clinical trials.

Every patient is different. Here are general considerations for helping your patients manage nausea[4,5]:

- Eat bland, low-fat foods such as crackers, toast, and rice.
- Eat foods that contain water, such as soup and gelatin.
- Don't lie down after you eat.
- Eat more slowly.
- Go outside and get some fresh air.

Important Safety Information (cont'd)

Warnings and Precautions (cont'd)

- **Acute Kidney Injury (cont'd):** Monitor renal function when initiating or escalating function when initiating or escalating doses of Wegovy® in patients reporting severe adverse gastrointestinal reactions and in patients with renal impairment reporting any adverse reactions that could lead to volume depletion

Please see additional Important Safety Information throughout.
Please click here for Prescribing Information, including Boxed Warning.

ONCE·WEEKLY wegovy® semaglutide injection 2.4 mg

What to know about prescribing Wegovy®

Tips for Prescribing

- If patients receive a starter kit that includes four 0.25 mg Wegovy® pens, check the "samples given" box in their EHR
  – Write prescription for 0.5 mg
- Encourage your patients to check in throughout their dose-escalation schedule to assess progress and tolerability
- After your patients reach their maintenance dose, you can consider a 3-month Rx
- Check to make sure the dispense quantity unit of measure is "mL" only
- Be sure to always choose "semaglutide for weight management" when searching the product database

Important to Remember

A new prescription is required for each dose strength

Integrated needle means no separate Rx or co-pay

Important Safety Information (cont'd)

Warnings and Precautions (cont'd)

- **Hypersensitivity Reactions:** Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with Wegovy®. If hypersensitivity reactions occur, discontinue use of Wegovy®, treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist
- **Diabetic Retinopathy Complications in Patients with Type 2 Diabetes:** In a trial of adult patients with type 2 diabetes, diabetic retinopathy was reported by 4.0% of Wegovy® patients and 2.7% of placebo patients. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy

How to prescribe once-weekly Wegovy®

Wegovy® comes in 5 packs (1 for each strength). Each pack contains 4 Wegovy® pens (1 pen for each week).[1]

	Strength	NDC	Days supply	Dispense quantity	Recommended Sig
STARTING dose	0.25 mg/0.5 mL	0169-4525-14	28 days	2 mL (mL only)	Inject 0.25 mg SC once weekly for 4 weeks (28 days)
	0.5 mg/0.5 mL	0169-4505-14	28 days	2 mL (mL only)	Inject 0.5 mg SC once weekly for 4 weeks (28 days)
	1 mg/0.5 mL	0169-4501-14	28 days	2 mL (mL only)	Inject 1 mg SC once weekly for 4 weeks (28 days)
3-month prescription can be written for 1.7 mg dose or 2.4 mg dose*	1.7 mg/0.75 mL	0169-4517-14	28 days	3 mL (mL only)	Inject 1.7 mg SC once weekly for 4 weeks (28 days)
			84 days*	9 mL* (mL only)	Inject 1.7 mg SC once weekly for 12 weeks (84 days*)
	2.4 mg/0.75 mL	0169-4524-14	28 days	3 mL (mL only)	Inject 2.4 mg SC once weekly for 4 weeks (28 days)
			84 days*	9 mL* (mL only)	Inject 2.4 mg SC once weekly for 12 weeks (84 days*)
	Dispense as written		Check the "dispense as written" (DAW) box		
	Note to pharmacy		Please dispense brand name Wegovy®, not to be confused with other semaglutide-containing products		

EHR, electronic health record; NDC, National Drug Code; SC, subcutaneous.

*A 3-month supply for appropriate patients would be dispensed as 3 packs, each containing 4 Wegovy® 1.7 mg or 2.4 mg dose single-use pens (1.7 mg/0.75 mL or 2.4 mg/0.75 mL) for a total dispense quantity of 9 mL.

Important Safety Information (cont'd)

Warnings and Precautions (cont'd)

- **Heart Rate Increase:** Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed in Wegovy® adult patients compared to placebo in clinical trials. More Wegovy® adult patients compared with placebo had maximum changes from baseline of 10 to 19 bpm (41% versus 34%) and 20 bpm or more (26% versus 16%). In a clinical trial in pediatric patients aged 12 years and older with normal baseline heart rate, more patients treated with Wegovy® compared to placebo had maximum changes in heart rate of 20 bpm or more (54% versus 39%).

Please see additional Important Safety Information throughout.
Please click here for Prescribing Information, including Boxed Warning.

ONCE·WEEKLY wegovy® semaglutide injection 2.4 mg

Start your patients on Wegovy® today for as little as $0*

Your patients may pay as little as

$0

For the first 12 prescriptions filled, patients may pay as little as $0 per 28-day supply (1 box) of Wegovy®

*Subject to maximum savings of $225 per 28-day supply (1 box) for up to 12 fills for commercially insured patients with Wegovy® coverage. Patients with commercial insurance who do not have coverage for Wegovy® can save $500 per 28-day supply (1 box). Offer must be activated by 12/31/23. Eligibility and other restrictions apply, see WegovyTerms.com for details. Novo Nordisk reserves the right to modify or cancel this program at any time.

Help your patients get started with Wegovy® in 3 easy steps:

- **Verify coverage in as little as 90 seconds**
- **Initiate a prior authorization, if needed**
- **Start Wegovy®**

Start the journey today at

WegovyCoverage.com

Important Safety Information (cont'd)

Warnings and Precautions (cont'd)

- **Heart Rate Increase (cont'd):** Monitor heart rate at regular intervals and instruct patients to report palpitations or feelings of a racing heartbeat while at rest. If patients experience a sustained increase in resting heart rate, discontinue Wegovy®
- **Suicidal Behavior and Ideation:** Suicidal behavior and ideation have been reported in clinical trials with other weight management products. Monitor patients for depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue Wegovy® in patients who experience suicidal thoughts or behaviors and avoid in patients with a history of suicidal attempts or active suicidal ideation

Adverse Reactions

- Most common adverse reactions (incidence ≥5%) are: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distention, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis

WeGo*Together*®

Personalized support for your patients

WeGo*Together*® is a program with behavior change resources designed to help your patients get started and stay on track with Wegovy®. ***This program is intended to complement, not replace, your care.***

Medication

Helpful tools available for Wegovy®, including:

- ☑ Tips for using their pen
- ☑ Ability to track dose
- ☑ Weekly text reminders to take medication

Motivation

- Coaching can be live via phone, text, or email based on patient preference
- Coaches guide patients to create SMART goals on portion control, sleep hygiene, physical activity, and more to support long-term change
- MHFA- and ADCES-certified coaches are trained in obesity and supporting lifestyle change based on patient's unique needs

Momentum

- Reframing behavior change from weight loss to long-term weight maintenance
- Tools, tips, and lifestyle content designed to help them maintain efforts for the long term
- A personalized web experience allows patients to track their progress and print their report to share with you

Patients are advised to consult their health care providers about treatment-related questions.
SMART, Specific Measurable Achievable Relevant Time-Bound; MHFA, Mental Health First Aid; ADCES, Association of Diabetes Care & Education Specialists.

Important Safety Information (cont'd)

Drug Interactions

- The addition of Wegovy® in patients treated with insulin has not been evaluated. When initiating Wegovy®, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia
- Wegovy® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor the effects of oral medications concomitantly administered with Wegovy®

Please see additional Important Safety Information throughout.
Please click here for Prescribing Information, including Boxed Warning.

ONCE·WEEKLY wegovy® semaglutide injection 2.4 mg

Start Wegovy®: The #1 prescribed medication for chronic weight management in the US*

Tips to consider when helping your patients on their Wegovy® journey

Actor portrayals.

START TODAY

At this initial visit, start your patient by prescribing Wegovy® 0.25 mg once weekly and consider:

Explaining the benefits of Wegovy® and how to manage potential side effects

Demonstrating how to use the Wegovy® pen and the dose-escalation schedule

Encouraging enrollment in WeGo*Together*® and when to schedule a follow-up to help patients stay on track with Wegovy®

STEP UP

Throughout dose escalation, think about:

Celebrating progress and emphasizing the importance of staying on therapy

Scheduling appointments after each new dose to measure progress

Writing a new prescription for each dose

STAY

Once your patient has reached their maintenance dose, consider:

Continuing measuring progress and monitoring side effects

Emphasizing the importance of staying on Wegovy® long term to help keep the weight off

Writing a 3-month prescription and initiate a PA reauthorization (if required)

Scheduling regular follow-ups

*Source: IQVIA Xponent Plantrak. Based on TRx for products indicated for chronic weight management for the period of Jul '22 through Jun '23.

Important Safety Information (cont'd)

Use in Specific Populations

- **Pregnancy:** May cause fetal harm. When pregnancy is recognized, discontinue Wegovy®. Discontinue Wegovy® in patients at least 2 months before a planned pregnancy
- **Pediatric:** Adverse reactions with Wegovy® in pediatric patients aged 12 years and older were similar to those reported in adults. Pediatric patients ≥12 years of age treated with Wegovy® had greater incidences of cholelithiasis, cholecystitis, hypotension, rash, and urticaria compared to adults treated with Wegovy®

Please see additional Important Safety Information throughout. Please click here for Prescribing Information, including Boxed Warning.

References: 1. Wegovy® [package insert]. Plainsboro, NJ: Novo Nordisk, Inc.; 2023. **2.** Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med*. 2021;384(11):989-1002. **3.** Data on file. Novo Nordisk Inc.; Plainsboro, NJ. **4.** When you have nausea and vomiting. Medline Plus website. Accessed November 15, 2022. https://medlineplus.gov/ency/patientinstructions/000122.htm **5.** Nausea and vomiting. *Cleveland Clinic*. Accessed November 15, 2022. https://my.clevelandclinic.org/health/symptoms/8106-nausea--vomiting

novo nordisk®

ONCE-WEEKLY wegovy® semaglutide injection 2.4 mg